RT Journal Article
SR Electronic
T1 Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5549
OP 5556
DO 10.21873/anticanres.15368
VO 41
IS 11
A1 ONDREJ VENCLICEK
A1 JANA SKRICKOVA
A1 KRISTIAN BRAT
A1 ONDREJ FISCHER
A1 LIBOR HAVEL
A1 MICHAL HRNCIARIK
A1 MILOSLAV MAREL
A1 PETR OPALKA
A1 GABRIELA KRAKOROVA
A1 DENISA ROZSIVALOVA
A1 JURAJ KULTAN
A1 ANDREA MULLEROVA
A1 LYDIA ZARNAYOVA
A1 PETRA SMICKOVA
A1 MARTINA VASAKOVA
A1 ZSUZSANNA GYORFY
A1 MICHAL JIROUSEK
A1 DANIEL KREJCI
A1 JANA KREJCI
A1 PETR ZUNA
A1 MARTIN SVATON
A1 KRISTYNA HRDA
A1 JAROSLAV DUBA
A1 JANA ALAHAKOON
A1 MICHAL SVOBODA
A1 JIRI SILAR
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5549.abstract
AB Background/Aim: LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018. The aim of the study was to assess the stage of the disease at the time of diagnosis, percentage of morphological types, survival, percentage of driving mutations, eligibility for radical surgery, and percentage of patients who undergo radical surgery, in the non-smoking population in comparison with smokers and former smokers. Patients and Methods: The total number of patients in the registry at the time of the analysis was 2,743. Only 2,439 patients with complete records (smoking status, stage, and type of tumor) were included in this study. Results: The analysis indicated that non-smokers are diagnosed at a later stage of the disease but they have a better survival rate than smokers. Fewer smokers with stage III disease who are eligible for radical surgery will undergo surgery compared to non-smokers with the same clinical stage. Driving mutations are more common in non-smokers, even after adjustment for the more frequent occurrence of adenocarcinoma in the group of non-smokers. Conclusion: The data from LUCAS registry are consistent with already known facts, suggesting that the LUCAS registry is a useful clinical tool.